Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Biosputnik LLC
Profile last edited on: 2/24/22      CAGE: 8FD18      UEI: J79GBT6Y9LE3

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
2019
First Award
2021
Latest Award
2021
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

504 Grand Street
New York, NY 10002
   N/A
   N/A
   www.biosputnik.org
Location: Single
Congr. District: 07
County: New York

Public Profile

With the founding principal of the firm currently focused on developing a set of small molecules in oncology, acute radiation syndrome, respiratory diseases and biologic vaccines, BioSputnik® LLC is broadly structured around R&D for novel therapies and products (and providing scientific & regulatory matters) with the principals providing consulting services in the life sciences space and conducting R&D for novel therapies and products.

Extent of SBIR involvement

User Avatar
Phase I Awards
1
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$256,400
Phase II Dollars
$0
Total Awarded
$256,400

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2021 1 NIH $256,400
Project Title: Nitazoxanide as a Novel Therapy for Rare Disease Lymphangioleiomyomatosis and Tuberous Sclerosis
0 1 NIH $299,997
Project Title: Novel Combination Therapy for Treatment and Prevention of PulmonaryLymphangioleiomyomatosis (LAM) and Tuberous Sclerosis Complex (TSC)
0 1 NIH $301,016
Project Title: miRNA-Nanotechnology as a novel regenerative therapy for lymphangioleiomyomatosis

Key People / Management

  Dirk Pleimes -- Founder: Chief Scientific and Medical Officer, Managing Director

  Vera P Krymskaya

Company News

There are no news available.